Weave Bio Raises $10M Funding to Streamline Therapeutic Lifecycle
Weave Bio is pioneering the integration of AI technology in life sciences to optimize regulatory processes and accelerate drug development, thereby transforming traditional approaches in the sector.
Company Name: Weave Bio
Location: New Haven, CT
Sector: Life Sciences, Artificial Intelligence
Funding Details: Raised $10M in funding. The investment round was led by Innovation Endeavors and Magnetic Ventures.
Purpose of Investment: To accelerate the development of its AI-native life sciences platform aimed at streamlining the therapeutic lifecycle.
Leadership: Led by CEO Ari Caroline.
Product: Weave Bio offers the Regulatory Automation and Lifecycle Management (ReALM) platform, designed specifically for the pharmaceutical and biotech industries. The platform’s flagship product, AutoIND, allows drug development teams to enhance the efficiency of the Investigational New Drug (IND) application process by utilizing AI to integrate users' own data, regulatory standards, and public information, creating a comprehensive and evolving record of therapeutic candidates.
About Company: Weave Bio is pioneering the integration of AI technology in life sciences to optimize regulatory processes and accelerate drug development, thereby transforming traditional approaches in the sector.
